Data updated: Jun 28, 2026
Rosacea Clinical Trial Landscape
Rosacea is being studied across 124 clinical trials registered since 2008, with 4 programs currently active. The competitive pipeline includes 0 active Phase 3 trials, 3 active Phase 2 trials, and 0 active Phase 1 trials.
Top industry sponsors include Tarsus Pharmaceuticals, Inc., Galderma R&D, LEO Pharma.
Trial activity
4 active / 124 total since 2008
Active by phase 0 Ph3 / 39 3 Ph2 / 46 0 Ph1 / 17 1 Ph4 / 22
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Tarsus Pharmaceuticals, Inc. 1 1 0
Galderma R&D 0 20 0
LEO Pharma 0 5 0
Sol-Gel Technologies, Ltd. 0 4 1
Maruho Co., Ltd. 0 5 0
Vyne Therapeutics Inc. 0 4 1
Actavis Inc. 0 5 0
AbbVie 0 5 0
Padagis LLC 0 4 0
CAGE Bio Inc. 0 3 0
Journey Medical Corporation 0 3 0
Sun Pharmaceutical Industries, Inc. 0 3 0
How the field has grown
New-trial starts peaked in 2017 (14 registered); 2025 saw 3. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (15 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 10
2017 14
2018 8
2019 4
2020 2
2021 6
2022 5
2023 5
2024 5
2025 3
2026 0
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (4) 649
2017 (4) 628
2018 (3) 372
2019 (2) 815
2020 (0) 0
2021 (0) 0
2022 (2) 327
2023 (0) 0
2024 (0) 0
2025 (0) 0
2026 (0) 0
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT05296629 COMPLETED
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Journey Medical Corporation n=323
NCT05343455 COMPLETED
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Journey Medical Corporation n=330
NCT01555463 COMPLETED
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
LEO Pharma n=961
NCT01659853 COMPLETED
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
Galderma R&D n=70
NCT02576860 COMPLETED
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
Maruho Co., Ltd. n=263
NCT02547441 COMPLETED
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
Maruho Co., Ltd. n=463
NCT02576847 COMPLETED
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
Maruho Co., Ltd. n=307
NCT03276936 COMPLETED
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
Vyne Therapeutics Inc. n=504
NCT03564119 COMPLETED
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
Sol-Gel Technologies, Ltd. n=372
NCT03564145 TERMINATED
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Sol-Gel Technologies, Ltd. n=547
NCT03448939 COMPLETED
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Sol-Gel Technologies, Ltd. n=361
NCT02800148 COMPLETED
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
Padagis LLC n=667
NCT03352323 COMPLETED
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Padagis LLC n=50
NCT02795117 COMPLETED
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
Padagis LLC n=486
NCT02385240 COMPLETED
Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
Padagis LLC n=552
NCT03954444 COMPLETED
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Actavis Inc. n=1,105
NCT01318733 COMPLETED
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Galderma R&D n=449
NCT01355471 COMPLETED
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Galderma R&D n=293
NCT01355458 COMPLETED
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Galderma R&D n=260
NCT03142451 COMPLETED
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Vyne Therapeutics Inc. n=751
NCT04608500 COMPLETED
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Vyne Therapeutics Inc. n=771
NCT04106726 COMPLETED
Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
Zydus Worldwide DMCC n=525
NCT02393937 COMPLETED
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
bioRASI, LLC n=963
NCT02120924 COMPLETED
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
Actavis Inc. n=1,009
NCT02289352 COMPLETED
Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
Actavis Inc. n=462
NCT02131636 COMPLETED
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Allergan n=440
NCT02132117 COMPLETED
Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
Allergan n=445
NCT02095158 COMPLETED
A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
Allergan n=440
NCT03287791 COMPLETED
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
Actavis Inc. n=924
NCT01493947 COMPLETED
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Galderma R&D n=962
NCT01789775 COMPLETED
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea
Galderma R&D n=114
NCT01016782 COMPLETED
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
Fougera Pharmaceuticals Inc. n=867
NCT00823901 COMPLETED
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
Massachusetts General Hospital n=83
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only